Novartis FY2026 EPS Estimate Boosted by Erste Group Bank

Novartis AG (NYSE:NVS) – Erste Group Bank upped their FY2026 EPS estimates for Novartis in a research note issued on Tuesday, September 8th. Erste Group Bank analyst H. Engel now forecasts that the company will post earnings per share of $8.99 for the year, up from their previous estimate of $8.95. The consensus estimate for Novartis’ current full-year earnings is $8.85 per share.

Novartis (NYSE:NVS) last released its earnings results on Tuesday, June 30th. The company reported $2.41 earnings per share for the quarter. The business had revenue of $14.95 billion for the quarter. Novartis had a return on equity of 38.56% and a net margin of 23.29%.

A number of other brokerages have also commented on NVS. Royal Bank Of Canada started coverage on Novartis in a research note on Tuesday, September 8th. They issued a “sector perform” rating for the company. HSBC set a $136.00 price target on shares of Novartis in a research note on Thursday. Deutsche Bank Aktiengesellschaft lowered shares of Novartis from a “buy” rating to a “hold” rating in a report on Tuesday, September 8th. Weiss Ratings reissued a “buy (b)” rating on shares of Novartis in a report on Friday, July 24th. Finally, Citigroup reiterated a “buy” rating on shares of Novartis in a research report on Wednesday, July 22nd. Six equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $153.00.

Novartis Price Performance

Shares of NVS stock opened at $139.17 on Monday. Novartis has a 12 month low of $121.57 and a 12 month high of $170.46. The company has a market capitalization of $265.55 billion, a P/E ratio of 20.99, a P/E/G ratio of 2.66 and a beta of 0.45. The stock has a 50 day moving average of $153.86 and a two-hundred day moving average of $152.72. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.89.

Institutional Investors Weigh In On Novartis

Institutional investors and hedge funds have recently modified their holdings of the business. Archer Investment Corp grew its holdings in shares of Novartis by 93.0% during the 1st quarter. Archer Investment Corp now owns 166 shares of the company’s stock worth $25,000 after purchasing an additional 80 shares in the last quarter. Highland Investment Advisors LLC bought a new position in Novartis in the 2nd quarter valued at about $25,000. Evolution Wealth Management Inc. raised its position in shares of Novartis by 552.0% in the 2nd quarter. Evolution Wealth Management Inc. now owns 163 shares of the company’s stock valued at $26,000 after buying an additional 138 shares in the last quarter. Atlatl Advisers LLC acquired a new position in shares of Novartis in the 2nd quarter valued at approximately $26,000. Finally, Nalls Sherbakoff Group LLC bought a new stake in shares of Novartis during the 4th quarter worth approximately $34,000. 13.12% of the stock is owned by institutional investors.

About Novartis

Novartis AG (NYSE: NVS) is a Switzerland-based pharmaceutical company focused on discovering, developing and commercializing innovative medicines. The company’s portfolio addresses major disease areas including cardiovascular, renal and metabolic conditions, immunology, neuroscience, oncology and hematology.

Novartis markets medicines such as Entresto for certain heart conditions, Cosentyx for inflammatory diseases, Kisqali for breast cancer, Kesimpta for multiple sclerosis, Leqvio for cholesterol management, Pluvicto for certain prostate cancers and Scemblix for chronic myeloid leukemia.